Aggressive Lymphomas
From the Journals
CAR T-cell therapy found safe, effective for HIV-associated lymphoma
Two HIV-positive patients with chemotherapy-refractory, high-grade B-cell lymphoma achieved complete remission with anti-CD19 CAR T-cell therapy,...
Conference Coverage
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomas
Development plans for anti-CD19, anti-CD20 therapy include phase 2 studies in mantle cell, CD19 CAR T cell relapsers.
Conference Coverage
5F9 plus rituximab take a bite out of drug-resistant NHL
AMSTERDAM – The combination thwarts a mechanism that non-Hodgkin lymphomas use to evade immune surveillance.
Conference Coverage
‘Encouraging’ responses seen with durvalumab plus R-CHOP in DLBCL
CHICAGO – Durvalumab plus R-CHOP induction produced a complete response rate of 54%.
Conference Coverage
Chemo-free Smart Start regimen looks promising in poor-prognosis DLBCL
CHICAGO – There was “oohing and aahing” over results showing high response and survival rates for combined rituximab, lenalidomide, and ibrutinib...
Conference Coverage
SC-PEG comparable to pegaspargase in young ALL/LL patients
CHICAGO – Patients who received SC-PEG had similar serum asparaginase activity, toxicities, and survival as patients...
News
FDA opts not to ban textured breast implants
Data link breast implant–associated anaplastic large cell lymphoma to textured devices, but the FDA allowed continued U.S. sales.
Conference Coverage
Monitoring, early intervention key to CAR T safety
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...
Commentary
Powerful breast-implant testimony constrained by limited evidence
SILVER SPRING, MD. – Women report personal horror stories of apparent breast-implant complications, but systematically-collected data remain...
Conference Coverage
UNITY-NHL: Interim findings show activity, tolerability of umbralisib for R/R MZL
ATLANTA – The phosphoinositide 3-kinase delta inhibitor is active as a single-agent therapy in patients with relapsed or refractory marginal zone...
Conference Coverage
FDA panel calls for changes to breast implant rupture screening
The advisory panel seemed the current implant screening recommendation using MRI “useless.” They urged the adoption of ultrasound as a more...